{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["7(10)"],"submitter":["Andres-Rozas M"],"pubmed_abstract":["<h4>Background & aims</h4>Steatotic liver disease can lead to the development of metabolic dysfunction-associated steatohepatitis (MASH), the prevalence of which is rapidly increasing, intensifying the need to find an effective treatment. GTX-11 is a first-in-class drug with anti-inflammatory and antifibrotic properties mediated by the modulation of the transforming growth factor beta pathway. The present study evaluated the effects of GTX-11 on hepatic hemodynamics and liver fibrosis, as well as its underlying mechanisms, in a preclinical model of MASH, and in human precision-cut liver slices (hPCLS).<h4>Methods</h4>Male Wistar MASH rats received GTX-11 (1 and 10 mg/kg/day) or vehicle, for 14 days (n = 15/group). <i>In vivo</i> systemic and hepatic hemodynamics, fibrosis, biochemical para"],"journal":["JHEP reports : innovation in hepatology"],"pagination":["101497"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12447985"],"repository":["biostudies-literature"],"pubmed_title":["GTX-11 improves portal hypertension, liver fibrosis, and sinusoidal cells phenotype in experimental MASH."],"pmcid":["PMC12447985"],"pubmed_authors":["Guixe-Muntet S","Boyer-Diaz Z","Garcia-Delgado N","Lozano JJ","Aristu-Zabalza P","Fuster C","Gracia-Sancho J","Andres-Rozas M","Ruiz-Canovas E","Mercade J","Fernandez-Asensio C","Bosch J"],"additional_accession":[]},"is_claimable":false,"name":"GTX-11 improves portal hypertension, liver fibrosis, and sinusoidal cells phenotype in experimental MASH.","description":"<h4>Background & aims</h4>Steatotic liver disease can lead to the development of metabolic dysfunction-associated steatohepatitis (MASH), the prevalence of which is rapidly increasing, intensifying the need to find an effective treatment. GTX-11 is a first-in-class drug with anti-inflammatory and antifibrotic properties mediated by the modulation of the transforming growth factor beta pathway. The present study evaluated the effects of GTX-11 on hepatic hemodynamics and liver fibrosis, as well as its underlying mechanisms, in a preclinical model of MASH, and in human precision-cut liver slices (hPCLS).<h4>Methods</h4>Male Wistar MASH rats received GTX-11 (1 and 10 mg/kg/day) or vehicle, for 14 days (n = 15/group). <i>In vivo</i> systemic and hepatic hemodynamics, fibrosis, biochemical para","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Oct","modification":"2026-06-03T17:02:00.402Z","creation":"2026-05-30T03:06:23.243Z"},"accession":"S-EPMC12447985","cross_references":{"pubmed":["40980160"],"doi":["10.1016/j.jhepr.2025.101497"]}}